The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2022

Filed:

Oct. 17, 2013
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Isaac Kinde, Beaumont, CA (US);

Kenneth W. Kinzler, Baltimore, MD (US);

Bert Vogelstein, Baltimore, MD (US);

Nickolas Papadopoulos, Towson, MD (US);

Luis Diaz, Ellicott City, MD (US);

Chetan Bettegowda, Perry Hall, MD (US);

Yuxuan Wang, Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); C12Q 1/6851 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/57442 (2013.01); G01N 33/57449 (2013.01); C12Q 1/6851 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01);
Abstract

The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.


Find Patent Forward Citations

Loading…